Crosspoint Capital Strategies’s iShares Biotechnology ETF IBB Stock Holding History

Crosspoint Capital Strategies’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-30	Closed	-$3K	–	146
2016 Q3	$3K	Hold	30	–	–	﹤0.01%	99
2016 Q2	$3K	Buy	+30	New	+$2.69K	﹤0.01%	106
2016 Q1	–	Sell	-3,420	Closed	-$346K	–	436
2015 Q4	$346K	Buy	3,420 +3,165	+1,241%	+$344K	0.09%	177
2015 Q3	$26K	Buy	255 +75	+42%	+$9K	0.03%	323
2015 Q2	$22K	Hold	180	–	–	0.01%	422
2015 Q1	$21K	Sell	180 -1,488	-89%	-$164K	0.01%	335
2014 Q4	$169K	Buy	1,668 +216	+15%	+$21K	0.06%	222
2014 Q3	$132K	Hold	1,452	–	–	0.1%	137
2014 Q2	$122K	Hold	1,452	–	–	0.05%	171
2014 Q1	$114K	Hold	1,452	–	–	0.05%	170
2013 Q4	$130K	Buy	+1,452	New	+$103K	0.04%	167

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Crosspoint Capital Strategies's IBB Position: Q4 2016 in Review

Crosspoint Capital Strategies sold out of iShares Biotechnology ETF (IBB) in Q4 2016, closing a stake of 30 shares — an estimated $3K sold.

Crosspoint Capital Strategies first reported a position in IBB in Q4 2013 and held it in 11 quarters. The position peaked at $346K in Q4 2015. 522 funds tracked by Wall St. Rank hold IBB as of Q4 2016.

Crosspoint Capital Strategies reported no remaining iShares Biotechnology ETF position as of Q4 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 30 iShares Biotechnology ETF shares in Q4 2016, an estimated $3K.
Crosspoint Capital Strategies first reported a position in iShares Biotechnology ETF in Q4 2013 and held it in 11 quarters.
Crosspoint Capital Strategies's iShares Biotechnology ETF position peaked at $346K in Q4 2015.
522 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2016, filed 23 Jan 2017.